CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to TOVX

VCN-01 oncolytic adenovirus (zabilugene almadenorepvec)

Phase 2
Theriva Biologics, Inc. (TOVX)

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Q3 '27
TOVXPhase 2

VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) Phase 2 Est. Readout

VCN-01 oncolytic adenovirus (zabilugene almadenorepvec)
Q3 2027~Q
CT.gov
00%
Competitive Landscape

0 competitors in Pancreas Cancer, Metastatic

View Full Landscape
Drug Information

Target Indication

Pancreas Cancer, Metastatic

Clinical Trial

NCT07701486

Last updated: 7/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.